[go: up one dir, main page]

MA34483B1 - Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante - Google Patents

Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante

Info

Publication number
MA34483B1
MA34483B1 MA35688A MA35688A MA34483B1 MA 34483 B1 MA34483 B1 MA 34483B1 MA 35688 A MA35688 A MA 35688A MA 35688 A MA35688 A MA 35688A MA 34483 B1 MA34483 B1 MA 34483B1
Authority
MA
Morocco
Prior art keywords
treatment
hypertension
prevention
heart failure
anticoagulant therapy
Prior art date
Application number
MA35688A
Other languages
English (en)
Inventor
Diego Albrecht
Priyamvada Chandra
Sven Godtfredsen
Pierre Jordaan
Martin Lefkowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34483(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34483B1 publication Critical patent/MA34483B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes et des compositions pharmaceutiques pour le traitement de l'hypertension et/ou la prévention ou le traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante à l'aide d'un ou de plusieurs composés qui sont thérapeutiquement efficaces mais n'ont pas d'impact sur le ou les effets pharmacocinétiques ou pharmacodynamiques de l'anticoagulant, tels que la warfarine.
MA35688A 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante MA34483B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37641710P 2010-08-24 2010-08-24
PCT/US2011/048542 WO2012027237A1 (fr) 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante

Publications (1)

Publication Number Publication Date
MA34483B1 true MA34483B1 (fr) 2013-08-01

Family

ID=44543868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35688A MA34483B1 (fr) 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante

Country Status (18)

Country Link
US (2) US20130158088A1 (fr)
EP (1) EP2608784B1 (fr)
JP (1) JP2013536230A (fr)
KR (1) KR101864865B1 (fr)
CN (1) CN103079554A (fr)
AU (1) AU2011293648B2 (fr)
BR (1) BR112013004192A2 (fr)
CA (1) CA2807830C (fr)
CL (1) CL2013000513A1 (fr)
ES (1) ES2702529T3 (fr)
GT (1) GT201300047A (fr)
MA (1) MA34483B1 (fr)
MX (1) MX341174B (fr)
PH (1) PH12013500231A1 (fr)
RU (1) RU2564941C2 (fr)
SG (1) SG187755A1 (fr)
TW (1) TW201208678A (fr)
WO (1) WO2012027237A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882771C (fr) * 2012-08-24 2021-02-23 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caracterisees par un agrandissement atrial ou une remodelisation atriale
EP3038653A1 (fr) * 2013-08-26 2016-07-06 Novartis AG Nouvelle utilisation
RS59816B1 (sr) * 2013-08-26 2020-02-28 Novartis Ag Nova primena
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN110938042B (zh) * 2014-12-08 2022-12-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
PT3411021T (pt) 2016-02-03 2025-08-06 Novartis Ag Nova utilização de uma combinação de sacubitril e valsartan
WO2017218418A1 (fr) * 2016-06-13 2017-12-21 The Board Of Regents Of The University Of Texas System Compositions et procédés de modélisation de l'insuffisance cardiaque à fraction d'éjection conservée
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US6869357B2 (en) * 2001-12-19 2005-03-22 Igt Methods of conducting games of chance and gaming devices with multiple pay lines
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US7857515B2 (en) * 2007-06-15 2010-12-28 S.C. Johnson Home Storage, Inc. Airtight closure mechanism for a reclosable pouch
NZ584686A (en) * 2007-11-06 2013-03-28 Novartis Ag Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate

Also Published As

Publication number Publication date
GT201300047A (es) 2014-07-08
EP2608784A1 (fr) 2013-07-03
TW201208678A (en) 2012-03-01
BR112013004192A2 (pt) 2016-05-10
MX341174B (es) 2016-08-10
RU2013112859A (ru) 2014-09-27
US20130158088A1 (en) 2013-06-20
PH12013500231A1 (en) 2017-08-09
SG187755A1 (en) 2013-03-28
WO2012027237A1 (fr) 2012-03-01
US20140329872A1 (en) 2014-11-06
KR20130095754A (ko) 2013-08-28
EP2608784B1 (fr) 2018-09-19
AU2011293648B2 (en) 2015-02-12
MX2013002212A (es) 2013-05-09
JP2013536230A (ja) 2013-09-19
CA2807830A1 (fr) 2012-03-01
CL2013000513A1 (es) 2014-08-29
RU2564941C2 (ru) 2015-10-10
KR101864865B1 (ko) 2018-06-05
AU2011293648A1 (en) 2013-03-21
CA2807830C (fr) 2018-04-03
ES2702529T3 (es) 2019-03-01
CN103079554A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
MA34483B1 (fr) Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA51530B1 (fr) Composés cycliques fondus
MA40290A1 (fr) Agents immunorégulateurs
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA54231A (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
TN2010000154A1 (fr) Composition destinee a la regulation du metabolism des lipides
MA37808A1 (fr) Composés et leurs utilisations thérapeutiques
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MA39972B1 (fr) Composés et compositions d'induction de la chondrogenèse
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MA38959A1 (fr) Modulateurs du facteur b du complément
MA42439B1 (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA35804B1 (fr) Modulation de l'expression du virus de l'hepatite b (vhb)
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA54386B1 (fr) Modulateurs de trex1
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA32360B1 (fr) Thérapie pour cancer hépatique
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
WO2018049003A8 (fr) Composés inhibiteurs de sialidase anti-fibrotique et leurs méthodes d'utilisation
FR2974300B1 (fr) Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c pour la prevention et/ou le traitement de desordres pigmentaires